Abstract:Objective: The objective of this study was to design a virtual screening (VS) protocol for identifying potential fibroblast growth factor receptor 4 (FGFR4) inhibitors from the commercially available Specs database. This was based on an experimental model of FGFR4 bound to the potent inhibitor FGF401 (PDB: 7VJL), with the aim of discovering novel compounds with therapeutic potential for various tumor types. Methods: The study comprised two main parts. Firstly, a ligand-based pharmacophore model was constructed using known potent FGFR4 inhibitors to discriminate between actives and decoys. Secondly, docking studies of the identified actives were conducted within the binding pocket of the FGFR4 experimental model. This aimed to assess the ability of the compounds to overlay on the reference inhibitor and interact similarly within the binding site. The virtual screening protocol was then applied to the Specs database to identify potential FGFR4 inhibitors. Results: The ligand-based pharmacophore model exhibited promising discrimination capabilities, achieving a true positive percentage of 100% and a false positive percentage of 7%. Docking studies revealed that the selected compounds overlaid well with the reference inhibitor and exhibited interactions within the FGFR4 binding pocket. Through the virtual screening of the Specs database, compound A emerged as the most suitable candidate. Molecular dynamics simulation and Molecular Mechanics Poisson-Boltzmann Surface Area (MMPBSA) calculations further supported the efficacy of compound A as a FGFR4 inhibitor. Additionally, compound A demonstrated favorable absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties, along with adherence to Lipinski’s rule of 5, enhancing its potential as a lead compound. Conclusion: In conclusion, compound A emerged as a promising selective FGFR4 inhibitor with potential for therapeutic use in various cancers. Further in vitro experiments and animal cancer model studies are warranted to validate its efficacy. The study highlights the effectiveness of the proposed virtual screening protocol in identifying novel FGFR4 inhibitors, offering a promising avenue for future drug discovery efforts in oncology.

Molecular Modeling Study of the Induced-Fit Effect on Kinase Inhibition: the Case of Fibroblast Growth Factor Receptor 3 (FGFR3).

Decoding the Conformational Selective Mechanism of FGFR Isoforms: A Comparative Molecular Dynamics Simulation

Mechanism of Kinase Inactivation and Nonbinding of FRATide to GSK3β Due to K85M Mutation: Molecular Dynamics Simulation and Normal Mode Analysis.

Molecular description of pyrimidine-based inhibitors with activity against FAK combining 3D-QSAR analysis, molecular docking and molecular dynamics

Binding Modes and Conformational Changes of FK506-binding Protein 51 Induced by Inhibitor Bindings: Insight into Molecular Mechanisms Based on Multiple Simulation Technologies

Investigations of FAK Inhibitors: a Combination of 3D-QSAR, Docking, and Molecular Dynamics Simulations Studies.

Structure-based drug-development study against fibroblast growth factor receptor 2: molecular docking and Molecular dynamics simulation approaches

Understanding the Selectivity of Inhibitors Toward PI4KIIIα and PI4KIIIβ Based Molecular Modeling

Molecular dynamics simulations reveal phosphorylation-induced conformational dynamics of the fibroblast growth factor receptor 1 kinase

Molecular Docking and Molecular Dynamics Simulations Reveal the Clinical Resistance of the Gatekeeper Mutation V564F of FGFR2 Against Infigratinib

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with -Substituent Electrophiles Targeting Cysteine

Structural Analysis of FGFR1 Kinase Activation Through Molecular Dynamics Simulation

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with alpha-Substituent Electrophiles Targeting Cysteine

Ligand based 3D-QSAR model, pharmacophore, molecular docking and ADME to identify potential fibroblast growth factor receptor 1 inhibitors

Exploring the interaction between human focal adhesion kinase and inhibitors: a molecular dynamic simulation and free energy calculations

Molecular Modeling Studies of Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Using QSAR and Docking.

Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification

Virtual Screening, Molecular Dynamics, MM-PBSA and In-silico Studies in Search of Potent Novel Fibroblast Growth Factor Receptors 4 Inhibitor

Molecular Dynamics Simulation and Free Energy Calculation Studies of the Binding Mechanism of Allosteric Inhibitors with P38α MAP Kinase.

Molecular Dynamics Analysis of Binding Sites of Epidermal Growth Factor Receptor Kinase Inhibitors

3D-QSAR, docking and molecular dynamics simulations of novel Pyrazolo-pyridazinone derivatives as covalent inhibitors of FGFR1: a scientific approach for possible anticancer agents